SUBSCRIBE
SUBSCRIBE

GondolaBio

NEWS
A top-down view of a business team holding a meeting
Startups
BridgeBio Launches GondolaBio With $300M, Transfers Programs to Joint Venture
With the help of third-party investors, the new venture will focus on three genetic and rare diseases: tuberous sclerosis complex, erythropoietic protoporphyria and alpha-A1 antitrypsin deficiency.
August 22, 2024
 · 
2 min read
 · 
Tristan Manalac
IN THE PRESS
Press Releases
GondolaBio and n-Lorem Foundation Partner to Advance Novel ASO Therapies for Genetic Diseases
December 17, 2024
 · 
6 min read
JOBS